BOL Boliden AB (publ)
Boliden AB (publ) engages in the extracting, producing, and recycling of base metals in Sweden, Finland, other Nordic region, Germany, the United Kingdom, Europe, North America, and internationally. The company operates through Business Area Mines and Business Area Smelters segments. It explores copper, zinc, nickel, lead, gold, silver, cobalt, sulphuric acid, tellurium, platinum, palladium, rhodium, iridium, ruthenium, and osmium deposits. The company operates the Aitik, the Boliden Area, and Garpenberg mines in Sweden; the Tara mine in Ireland; the Kevitsa mines in Finland; the Somincor mine in Portugal; Kokkola smelters in Finland; Odda zinc smelters in Norway; the Rönnskär smelter in Sweden; Harjavalta copper smelters in Finland; and the Bergsöe lead smelter in Sweden. It sells its metals primarily to industrial customers. The company was founded in 1924 and is headquartered in Stockholm, Sweden.…
Industry Peers
Other Industrial Metals & MiningKey Statistics
About Boliden (STO: BOL)
›
Boliden (STO: BOL) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Other Industrial Metals & Mining industry, part of the Basic Materials sector, and reports about 8,000 employees.
The shares were at 461.30 SEK on 19 November 2026, up 7.9% over 52 weeks. Its 52-week range is 403.40 SEK to 727.80 SEK: the price is 36.6% below the high and 14.4% above the low.
At a market capitalisation of 130.99B SEK, it trades at 9.2 times trailing earnings and 15.1 times forward earnings. The median trailing P/E of its 17 largest Other Industrial Metals & Mining peers is 13.6, a discount of 32% for BOL. It pays a dividend yielding 2.39% (it pays out 22% of its earnings), against a median of 4.45% among the dividend payers in that peer group.
Boliden reports return on equity of 12.3%, an operating margin of 17.0% and revenue up 38.6% year over year.
Its debt exceeds its cash by 17.77B SEK, a debt-to-equity ratio of 0.31. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 15 analysts cover the stock, with an average rating of Hold; their mean price target of 570.93 SEK is 23.8% above the current price. The next earnings report is expected on 3 February 2027.